Zhanbo Wang

机构：Shandong University, Wuhan University of Technology, Chinese PLA General Hospital, Shandong Management University, Chengde Medical University

发表论文 65 篇 · 总被引 810 次 · h-index 15

代表论文

• Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial (2023 · Journal for ImmunoTherapy of Cancer · 被引 131)
• Expert Consensus on Pathological Diagnosis of Intrahepatic Cholangiocarcinoma (2022 version) (2023 · Journal of Clinical and Translational Hepatology · 被引 21)
• Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition) (2024 · BioScience Trends · 被引 20)
• Multiparametric US for Identifying Metabolic Dysfunction–associated Steatohepatitis: A Prospective Multicenter Study (2024 · Radiology · 被引 19)
• Preparation of mechanically robust, self-healing superhydrophobic coatings based on novel fluorinated polyurethane via a “two-step” polycondensation process for applications in self-cleaning and anti-icing (2025 · Progress in Organic Coatings · 被引 11)
• The role of 18F−FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy (2023 · Frontiers in Immunology · 被引 11)